539524 Stock Overview Operates laboratories for carrying out pathological investigations in India and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Dr. Lal PathLabs Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Dr. Lal PathLabs Historical stock prices Current Share Price ₹2,851.65 52 Week High ₹3,645.00 52 Week Low ₹1,943.20 Beta 0.34 1 Month Change -4.96% 3 Month Change -7.67% 1 Year Change 16.40% 3 Year Change -7.69% 5 Year Change 76.31% Change since IPO 246.01%
Recent News & Updates
Third quarter dividend of ₹6.00 announced Feb 01
Third quarter 2025 earnings: EPS misses analyst expectations Jan 31
Dr. Lal Pathlabs Limited Approves Declaration Third Interim Dividend for Financial Year 2024-25 Jan 30
Dr. Lal PathLabs Limited to Report Q3, 2025 Results on Jan 30, 2025 Jan 23
Non Executive Director recently sold ₹15m worth of stock Jan 07
MD & Director recently sold ₹79m worth of stock Dec 12 See more updates
Third quarter dividend of ₹6.00 announced Feb 01
Third quarter 2025 earnings: EPS misses analyst expectations Jan 31
Dr. Lal Pathlabs Limited Approves Declaration Third Interim Dividend for Financial Year 2024-25 Jan 30
Dr. Lal PathLabs Limited to Report Q3, 2025 Results on Jan 30, 2025 Jan 23
Non Executive Director recently sold ₹15m worth of stock Jan 07
MD & Director recently sold ₹79m worth of stock Dec 12
MD & Director recently sold ₹35m worth of stock Nov 24
Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock Nov 08
Upcoming dividend of ₹6.00 per share Oct 29
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 24 Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025
Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024 Oct 16
MD & Director recently sold ₹28m worth of stock Aug 20
Price target increased by 7.2% to ₹2,794 Aug 08
First quarter 2025 earnings: EPS exceeds analyst expectations Aug 08
Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25 Aug 07
Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024 Jul 31
Non Executive Director recently sold ₹14m worth of stock Jul 02
MD & Director recently sold ₹20m worth of stock Jun 25
MD & Director recently sold ₹28m worth of stock Jun 13
MD & Director recently sold ₹37m worth of stock Jun 04
Upcoming dividend of ₹6.00 per share Jun 03
MD & Director recently sold ₹29m worth of stock May 29
MD & Director recently sold ₹36m worth of stock May 17 Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024
Full year 2024 earnings: Revenues and EPS in line with analyst expectations May 11
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 May 11
Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024 May 05
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024 Apr 28
MD & Director recently sold ₹33m worth of stock Mar 26
MD & Director recently sold ₹23m worth of stock Mar 09
MD & Director recently sold ₹43m worth of stock Feb 18
Upcoming dividend of ₹12.00 per share at 0.7% yield Feb 06
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Feb 02
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24 Feb 01
Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024 Jan 25
Chief Executive Officer recently sold ₹7.6m worth of stock Dec 24
Chief Executive Officer recently sold ₹2.6m worth of stock Dec 16
Non Executive Director recently sold ₹7.8m worth of stock Nov 11
Price target increased by 8.0% to ₹2,353 Nov 07
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 03
Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023 Oct 26
MD & Director recently sold ₹43m worth of stock Oct 01
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023 Sep 13
Dr. Lal PathLabs Limited Announces Change in Directorate Aug 22
Dr. Lal PathLabs Limited Announces Change in Directorate Aug 21
MD & Director recently sold ₹32m worth of stock Aug 12
Upcoming dividend of ₹12.00 per share at 0.5% yield Aug 04
Price target increased by 7.2% to ₹2,091 Jul 29
Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023 Jul 29
Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24 Jul 28
First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023) Jul 28
MD & Director recently sold ₹41m worth of stock Jun 10
MD & Director recently sold ₹43m worth of stock May 19 Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary
Full year 2023 earnings: EPS and revenues miss analyst expectations May 12
MD & Director recently sold ₹14m worth of stock Mar 26
MD & Director recently sold ₹48m worth of stock Mar 02
MD & Director recently sold ₹41m worth of stock Feb 18
Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023 Feb 14
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 05
Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million. Jan 31
Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023 Jan 24
Chief Executive Officer recently sold ₹3.6m worth of stock Dec 27
MD & Director recently sold ₹48m worth of stock Dec 16
MD & Director recently sold ₹61m worth of stock Dec 04
MD & Director recently sold ₹57m worth of stock Nov 25
Insufficient new directors Nov 16
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 09
Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022 Nov 02
MD & Director recently sold ₹33m worth of stock Sep 14
Non Executive Director recently sold ₹2.5m worth of stock Aug 24
MD & Director recently sold ₹117m worth of stock Aug 05
Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022 Jul 29
First quarter 2023 earnings: EPS misses analyst expectations Jul 29
Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022 Jul 21
Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022 Jul 01
Non-Executive Director recently sold ₹164m worth of stock Jun 24
Price target decreased to ₹2,536 Jun 18
Upcoming dividend of ₹6.00 per share Jun 15
Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022 Jun 10
Investor sentiment improved over the past week Jun 01
Chief Executive Officer recently sold ₹4.0m worth of stock May 27
Consensus EPS estimates fall by 16% May 24
Price target decreased to ₹2,829 May 19
Dr. Lal Pathlabs Limited Proposes Final Dividend for the Year Ended March 31, 2022 May 18
Full year 2022 earnings: EPS and revenues miss analyst expectations May 18
Dr. Lal PathLabs Limited, Annual General Meeting, Jun 30, 2022 May 18
Dr. Lal PathLabs Limited to Report Q4, 2022 Results on May 17, 2022 May 07
Insufficient new directors Apr 27
Insufficient new directors Apr 01
Insider recently sold ₹1.4m worth of stock Mar 24
MD & Director recently sold ₹36m worth of stock Mar 13
Insufficient new directors Mar 02
MD & Director recently sold ₹37m worth of stock Feb 27
Insider recently sold ₹2.7m worth of stock Feb 20
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 13 Shareholder Returns 539524 IN Healthcare IN Market 7D 0.9% 1.2% 0.9% 1Y 16.4% 20.9% 6.9%
See full shareholder returns
Return vs Market: 539524 exceeded the Indian Market which returned 6.8% over the past year.
Price Volatility Is 539524's price volatile compared to industry and market? 539524 volatility 539524 Average Weekly Movement 3.8% Healthcare Industry Average Movement 5.3% Market Average Movement 6.3% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.3%
Stable Share Price: 539524 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 539524's weekly volatility (4%) has been stable over the past year.
About the Company Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs.
Show more Dr. Lal PathLabs Limited Fundamentals Summary How do Dr. Lal PathLabs's earnings and revenue compare to its market cap? 539524 fundamental statistics Market cap ₹237.72b Earnings (TTM ) ₹4.17b Revenue (TTM ) ₹24.04b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 539524 income statement (TTM ) Revenue ₹24.04b Cost of Revenue ₹10.17b Gross Profit ₹13.88b Other Expenses ₹9.71b Earnings ₹4.17b
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) 50.03 Gross Margin 57.71% Net Profit Margin 17.34% Debt/Equity Ratio 9.8%
How did 539524 perform over the long term?
See historical performance and comparison Dividends
0.6% Current Dividend Yield When do you need to buy 539524 by to receive an upcoming dividend? Dr. Lal PathLabs dividend dates Ex Dividend Date Feb 05 2025 Dividend Pay Date Mar 01 2025 Days until Ex dividend 3 days Days until Dividend pay date 27 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 06:40 End of Day Share Price 2025/01/31 00:00 Earnings 2024/12/31 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Dr. Lal PathLabs Limited is covered by 47 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Nitin Bhasin Ambit Capital Prashant Nair Ambit Capital null null Antique Stockbroking Ltd.
Show 44 more analysts 
